Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402643 | 0.83 | MAOB (0.34) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL7448616 | 0.83 | MEN1 (0.33) | PDE4BMEN1LMNAMAPTHTT | |
| SCHEMBL6607050 | 0.71 | — | — | |
| SCHEMBL12316702 | 0.69 | LMNA (0.37) | MEN1LMNAMAPTKMT2A | |
| SCHEMBL7448622 | 0.68 | MAP3K14 (0.42) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL6023181 | 0.65 | PDE4A (0.33) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL5477746 | 0.64 | MAP3K14 (0.35) | — | |
| SCHEMBL5399566 | 0.63 | MEN1 (0.36) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL5410275 | 0.63 | MAOB (0.34) | MEN1LMNAMAPTKMT2A | |
| SCHEMBL12316691 | 0.63 | LMNA (0.49) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249578-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-7241757-B2 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2007-07-10 | — | — | US | disclosed |
| US-20040186090-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | disclosed |
| US-6750243-B1 | COMPETITIVE INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASES, ESPECIALLY THROMBIN; chemical synthesis; anticoagulants; treatment of thrombosis | AstraZeneća AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1140820-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1140820-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035869-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249578-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, TFPI | PDE4B 2389/4885MEN1 1056/4885LMNA 1125/4885 |
| US-20040186090-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | PDE4B 2901/4885MEN1 1587/4885LMNA 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.